Forum für Wissenschaft, Industrie und Wirtschaft

Home Fachgebiete Studien Analysen Nachricht

Deep brain stimulation reduces epileptic seizures in patients with refractory partial and secondarily generalized seizures

nächste Meldung

This multi-center clinical trial determined that the benefits of stimulation of the anterior nuclei of thalamus for epilepsy (SANTE) persisted and by 2 years there was a 56% reduction in seizure frequency. Full findings of this study are available early online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

Epilepsy, a common neurological disorder, is characterized by recurrent seizures that can cause temporary loss of consciousness, convulsions, confusion or disturbances in sensations. According to the World Health Organization (WHO), epilepsy affects 50 million people worldwide. Past studies indicate that one-third of those with epilepsy do not respond adequately to antiepileptic drugs (AEDs).

"Electrical deep brain stimulation (DBS) is a promising therapy for epilepsy," said Robert Fisher, M.D., Ph.D., Director of the Epilepsy Center at Stanford University, and lead author of the SANTE study. "Our goal is to find treatments that reduce the effects of epilepsy, particularly for those who don't respond to AED therapy."

The SANTE clinical trial included 110 participants, 18-65 years of age with partial seizures occurring at least 6 times per month (not more than 10 per day), and whose seizures failed to respond to at least 3 AED treatments. After a 3-month baseline with stable AED use, DBS electrodes were implanted in the anterior nuclei of thalamus (ANT) bilaterally using a stereotactic technique. One month after implantation, participants were randomized to stimulation at 5 V or no stimulation at 0 V (control group), using 90 µs pulses, 145 pulses/s, "ON" 1 minute, and "OFF" 5 minutes in a 3-month blinded treatment phase. (month 1 to month 4). All participants then received stimulation (from month 4 to month 13) in an unblinded "open label" phase of the trial.

Results showed those in the stimulation group had a 40.4% decline in seizures compared with 14.5% decline in the control group (blinded phase), and this difference was statistically significant, provided that seizures occurring in one patient transiently triggered by the stimulation cycle were discounted. Complex partial seizures, seizures listed as "most severe" by the subject and injuries from seizures all were reduced during the blinded phase in the stimulated group. Responder rate, (the percentage of patients whose seizures were cut in half or better) did not differ in the blinded phase, but improved long-term with respect to baseline.

Long-term follow-up began at 13 months post-implantation and included 105 participants all receiving stimulation. At 13 months, 41% of patients showed a reduction in seizures; at 25 months, 56% of patients experienced a reduction. Two participants were seizure-free from months 4-13 and 14 (12.7%) were seizure-free for at least 6 months of the trial. During the trial, no participant had symptomatic hemorrhage or brain infection. Researchers noted 5 deaths, none believed to be related to implantation or stimulation. Subjects in the stimulated group more often reported subjective depression and memory impairments, usually extensions of pre-exisitng problems.

"We found that bilateral DBS of the ANT does reduce seizure frequency in patients unresponsive to other treatments," concluded Dr. Fisher. The SANTE research team noted improvements in some participants who previously were not helped by multiple AEDs, vagus nerve stimulation, or epilepsy surgery. "While our study did not produce serious complications, DBS therapy is invasive and serious complications can occur," Dr. Fisher cautioned. "Additional clinical knowledge would help to determine the best candidates for DBS therapy and establish ideal stimulation parameters."

On March 12, 2010, an FDA advisory panel recommended approval of DBS in the anterior nucleus of thalamus as being safe and effective for patients with severe and refractory partial seizures with or without secondary generalization.

Article: "Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy." Robert Fisher, Vicenta Salanova, Thomas Witt, Robert Worth, Thomas Henry, Robert Gross, Kalarickal Oommen, Ivan Osorio, Jules Nazzaro, Douglas Labar, Michael Kaplitt, Michael Sperling, Evan Sandok, John Neal, Adrian Handforth, John Stern, Antonio DeSalles, Steve Chung, Andrew Shetter, Donna Bergen, Roy Bakay, Jaimie Henderson, Jacqueline French, Gordon Baltuch, William Rosenfeld, Andrew Youkilis, William Marks, Paul Garcia, Nicolas Barbaro, Nathan Fountain, Carl Bazil, Robert Goodman, Guy McKhann, K. Babu Krishnamurthy, Steven Papavassiliou, Charles Epstein, John Pollard, Lisa Tonder, Joan Grebin, Robert Coffey, Nina Graves, and the SANTE Study Group. Epilepsia; Published Early Online: March 18, 2010 (DOI: 10.1111/j.1528-1167.2010.02536.x).

This study is published in Epilepsia. Media wishing to receive a PDF of this article may contact medicalnews@wiley.com

Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. For more information, please visit http://www3.interscience.wiley.com/journal/117957420/home

Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or www.interscience.wiley.com.

Dawn Peters | Quelle: EurekAlert!
Weitere Informationen: www.wiley.com

nächste Meldung